Patrick Miqueu

Patrick Miqueu

Auto-generated profile, based on publicly available information

Patrick Miqueu

Institut National de la Santé et de la Recherche Médicale INSERM U1064, France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PSPervinder Sagoo
Pervinder Sagoo
EPEsperanza Perucha
Esperanza Perucha
BSBirgit Sawitzki
Birgit Sawitzki
STStefan Tomiuk
Stefan Tomiuk
DSDavid A. Stephens
David A. Stephens
RLRobert I. Lechler
Robert I. Lechler
Identifying transplant recipients in whom immunological tolerance is established or is developing would allow an individually tailored approach to their posttransplantation management. In this study, we aimed to develop reliable and reproducible in vitro assays capable of detecting tolerance in renal transplant recipients. Several biomarkers and bioassays were screened on a training set that included 11 operationally tolerant renal transplant recipients, recipient groups following different immunosuppressive regimes, recipients undergoing chronic rejection, and healthy controls. Highly predictive assays were repeated on an independent test set that included 24 tolerant renal transplant recipients. Tolerant patients displayed an expansion of peripheral blood B and NK lymphocytes, fewer activated CD4+ T cells, a lack of donor-specific antibodies, donor-specific hyporesponsiveness of CD4+ T cells, and a high ratio of forkhead box P3 to α-1,2-mannosidase gene expression. Microarray analysis further revealed in tolerant recipients a bias toward differential expression of B cell–related genes and their associated molecular pathways. By combining these indices of tolerance as a cross-platform biomarker signature, we were able to identify tolerant recipients in both the training set and the test set. This study provides an immunological profile of the tolerant state that, with further validation, should inform and shape drug-weaning protocols in renal transplant recipients.

1 September 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JHJames Alexander Hutchinson
James Alexander Hutchinson
PRPaloma Riquelme
Paloma Riquelme
BSBirgit Sawitzki
Birgit Sawitzki
STStefan Tomiuk
Stefan Tomiuk
PMPatrick Miqueu
Patrick Miqueu
FFFred Fändrich
Fred Fändrich
Regulatory macrophages (M regs) were administered to two living-donor renal transplant recipients. Both patients were minimized to low-dose tacrolimus monotherapy within 24 wk of transplantation and subsequently maintained excellent graft function. After central venous administration, most M regs remained viable and were seen to traffic from the pulmonary vasculature via the blood to liver, spleen, and bone marrow. By 1 y posttransplantation, both patients displayed patterns of peripheral blood gene expression converging upon the IOT-RISET signature. Furthermore, both patients maintained levels of peripheral blood FOXP3 and TOAG-1 mRNA expression within the range consistent with nonrejection. It is concluded that M regs warrant further study as a potential immune-conditioning therapy for use in solid-organ transplantation. The results of this work are being used to inform the design of The ONE Study, a multinational clinical trial of immunomodulatory cell therapy in renal transplantation.

1 January 2014 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RBRosa Bacchetta
Rosa Bacchetta
BLBarbarella Lucarelli
Barbarella Lucarelli
CSClaudia Sartirana
Claudia Sartirana
SGSilvia Gregori
Silvia Gregori
MSMaria T. Lupo Stanghellini
Maria T. Lupo Stanghellini
MRMaria-Grazia Roncarolo
Maria-Grazia Roncarolo
T-cell therapy after hematopoietic stem cell transplantation (HSCT) has been used alone or in combination with immunosuppression to cure hematologic malignancies and to prevent recurrence. Here, we describe the outcome of patients with high-risk/advanced stage hematologic malignancies, who received T-cell depleted (TCD) haploidentical-HSC transplantation (haplo-HSCT) combined with donor T lymphocytes pretreated with IL-10 (ALT-TEN trial). IL-10 anergized donor T cells (IL-10 DLI) contained T regulatory type 1 (Tr1) cell specific for the, host alloantigens, limiting donor-vs-host reactivity, and memory T cells able to respond to pathogens. IL-10 DLI were infused in 12 patients with the goal of improving immune-reconstitution after haplo-HSCT without increasing the risk of GvHD. IL-10 DLI led to fast immune-reconstitution in five patients. In four out of the five patients, total T-cell counts, TCR-Vβ repertoire and T-cell functions progressively normalized after IL-10 DLI. These four patients are alive, in complete disease remission and immune suppression-free at 7.2 years (median follow-up) after haplo-HSCT. Transient GvHD was observed in the immune reconstituted patients, despite persistent host-specific hypo-responsiveness of donor T cells in vitro and enrichment of cells with Tr1- specific biomarkers in vivo. Gene expression profiles of immune-reconstituted patients showed a common signature of tolerance. This study provides the first indication of the feasibility of Tr1 cell-based therapy and paves the way for the use of these Tr1 cells as adjuvant treatment for malignancies and immune-mediated disorders.

1 February 2007 in Molecular Immunology
Verified
Journal Article
Closed access
PMPatrick Miqueu
Patrick Miqueu
MGMarina Guillet
Marina Guillet
Nicolas DegauqueNicolas Degauque
Nicolas Degauque
JDJean-Christophe Doré
Jean-Christophe Doré
JSJean-Paul Soulillou
Jean-Paul Soulillou
SBSophie Brouard
Sophie Brouard

1 November 2006 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CBC. Ballet
C. Ballet
GRG. Roussey-Kesler
G. Roussey-Kesler
JAJ.-T. Aubin
J.-T. Aubin
SBS. Brouard
S. Brouard
MGM. Giral
M. Giral
JSJ.-P. Soulillou
J.-P. Soulillou
Rare kidney allograft recipients enjoy unaltered graft function years after interruption of their immunosuppressive treatment. To assess the extent to which this state of 'operational tolerance' (TOL) is specific to the graft and not the result of a global immunodeficiency, we analyzed the response of such patients following influenza vaccination. Hemagglutination inhibition titers and frequency of IFNgamma-secreting T cells were measured before 1 and 3 months after vaccination. The proportion of healthy volunteers (HV) responding to vaccine was significantly higher than that of immunosuppressed (IS) patients. Three 'TOL' patients presented a humoral response similar to that of HV, whereas the two others had a poor response, like the IS recipients. Although the small number of patients does not allow for definitive conclusions to be made, these data suggest that the status of tolerance may be heterogeneous, with some patients with a global immunodeficiency and others with an adapted response to vaccination.

15 August 2013 in Transplantation
Verified
Journal Article
Closed access
VDVincent Donckier
Vincent Donckier
LCLigia Craciun
Ligia Craciun
PMPatrick Miqueu
Patrick Miqueu
RTRoberto Ivan Troisi
Roberto Ivan Troisi
VLValerio Lucidi
Valerio Lucidi
MGMichel Goldman
Michel Goldman
Background We report on a pilot study investigating the feasibility of early immunosuppression withdrawal after liver transplantation (LT) using antithymocyte globulin (ATG) induction and rapamycin. Methods LT recipients received 3.75 mg/kg per day ATG from days 0 to 5 followed by rapamycin-based immunosuppression. In the absence of acute rejection (AR), rapamycin was withdrawn after month 4. Immunomonitoring included analysis of peripheral T-cell phenotypes and clonality, cytokine production in mixed lymphocyte reaction, and characterization of intragraft infiltrating cells. Results Ten patients were enrolled between October 2009 and July 2010. In the first three patients, complete withdrawal of immunosuppression after month 4 led to AR. No further withdrawals of immunosuppressive were attempted. Two AR occurred in the remaining seven patients. ATG induced profound T-cell depletion followed by CD8+ T-cell reexpansion exhibiting memory/effector-like phenotype associated with progressive oligoclonal T-cell expansion (Vβ/HPRT ratio) and gradually enhanced anti-cytomegalovirus and anti–Epstein-Barr virus T-cell frequencies. Patients developing AR were characterized by decreased TCAIM expression. AR were associated with increased donor-specific production of interferon (IFN)-γ and interleukin (IL)-17, increased intragraft expression of IFN-γ mRNA, and significant CD8+ T-cell infiltrates colocalizing with IL-17+ cells. Conclusion High-dose ATG followed by short-term rapamycin treatment failed to promote early operational tolerance to LT. AR correlates with expansion of memory-type CD8+ T cells and increased levels of IFN-γ and IL-17 in mixed lymphocyte reaction and in the graft. This suggests that resistance and preferential expansion of effector memory T-cell in lymphopenic environment could represent the major barrier for establishment of tolerance to LT in approaches using T-cell–depleting induction.